TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals priced a $130 million underwritten public offering consisting of 6.875 million shares of common stock at $16.00 per share and 1.25 million pre-funded warrants at $15.999 per warrant. The offering is expected to close on January 9, 2026, with net proceeds intended for general corporate purposes including working capital, commercialization, and R&D expenses. Guggenheim Securities and Cantor are serving as joint bookrunning managers.

Insights
JPMpC   neutral

Participating as lead bank in the bridge loan syndicate without significant additional context


PHAT   positive

The company successfully priced a substantial $130 million capital raise, demonstrating investor confidence and providing significant funding for commercialization and R&D activities. This capital infusion supports the company's growth strategy for its marketed GI disease treatments.